10-K: Procept BioRobotics Reports Strong Revenue Growth in 2024, Narrows Net Loss

Procept BioRobotics' 2024 10-K filing reveals significant revenue growth driven by increased adoption of their Aquablation therapy, alongside a reduction in net losses.

Summary

• Procept BioRobotics, a surgical robotics company, reported a revenue increase of 65% to $224.5 million for the year ended December 31, 2024, compared to $136.2 million in 2023.
• The company's net loss decreased from $105.9 million in 2023 to $91.4 million in 2024.
• The growth was primarily driven by increased sales volumes of both robotic systems and single-use disposable handpieces.
• As of December 31, 2024, Procept BioRobotics had an install base of 647 AquaBeam and HYDROS Robotic Systems globally, with 505 in the United States.
• The company's gross margin improved to 61% in 2024 from 52% in 2023, attributed to higher sales volumes and better management of manufacturing overhead costs.
• Research and development expenses increased to $62.3 million, reflecting ongoing investments in product improvements and next-generation technologies.
• Selling, general, and administrative expenses rose to $171.4 million due to the expansion of the commercial infrastructure.
• Procept BioRobotics believes its existing cash and cash equivalents, along with anticipated revenue, will be sufficient to fund operations for at least the next 12 months.
• The company is focused on growing its install base, increasing system utilization, and continuing to build clinical evidence to support the adoption of Aquablation therapy.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and improving financial performance. While the company is not yet profitable, the trends suggest a promising trajectory.

Positives

• Significant revenue growth indicates increasing market adoption of Aquablation therapy.
• Decreasing net losses suggest improved operational efficiency and progress towards profitability.
• Improved gross margin reflects better cost management and economies of scale.
• Positive coverage decisions from Medicare and commercial payors facilitate greater patient access to Aquablation therapy.
• The company's strong relationships with key opinion leaders and urological societies support broader acceptance of Aquablation therapy.

Negatives

• The company continues to incur net losses, indicating that it has not yet achieved profitability.
• Operating expenses, particularly SG&A, remain high due to ongoing investments in commercial infrastructure.
• The company relies on single-source suppliers for certain components, making it vulnerable to supply shortages and price fluctuations.
• The company is subject to extensive government regulation and oversight, which could lead to enforcement actions and penalties.

Risks

• The company's future success depends on the degree of market acceptance of its products among hospitals, surgeons, and patients.
• The company faces competition from larger companies with greater financial, technical, and marketing resources.
• The company may not be able to maintain adequate levels of third-party coverage and reimbursement for its products.
• The company's information technology systems may fail or suffer security breaches, which could negatively affect its business.
• The company may be subject to product liability lawsuits, which could result in substantial liabilities and limit its ability to sell its products.

Future Outlook

The company expects its revenue to increase in absolute dollars for the foreseeable future as it continues to focus on driving adoption of Aquablation therapy and increased system utilization. The company believes that its existing cash and cash equivalents and anticipated revenue will be sufficient to meet its capital requirements and fund its operations through at least the next twelve months.

Management Comments

• The company is focused on driving adoption of Aquablation therapy among urologists that perform hospital-based resective BPH surgery.
• The company intends to leverage its relationships with urologists to drive utilization of Aquablation therapy beyond the current surgical market.
• The company plans to leverage successes in active discussions with private payors to establish additional positive national and regional coverage policies.
• The company is committed to continuing to build upon its foundation of clinical evidence, which it believes will help drive increased awareness and adoption of its products.
• The company is currently developing additional and next generation technologies to support and improve Aquablation therapy to further satisfy the evolving needs of surgeons and their patients as well as to further enhance the usability and scalability of its products.

Industry Context

The announcement reflects a growing trend in the medical device industry towards minimally invasive surgical solutions and the increasing adoption of robotic-assisted procedures. Procept BioRobotics is positioning itself to capitalize on the growing market for BPH treatment, driven by an aging population and increasing awareness of surgical options.

Comparison to Industry Standards

• Compared to companies like Boston Scientific and Teleflex, Procept BioRobotics is a smaller player focused specifically on BPH treatment.
• The company's revenue growth rate of 65% significantly outpaces the average growth rate for the medical device industry, indicating strong market traction.
• The company's focus on clinical evidence and guideline inclusion aligns with industry best practices for driving adoption of new medical technologies.
• The company's gross margin of 61% is comparable to other medical device companies with established product lines.

Stakeholder Impact

• Shareholders: The strong revenue growth and improving financial performance are positive for shareholders.
• Employees: The company's growth and expansion create opportunities for career advancement and development.
• Customers: The company's focus on innovation and clinical evidence aims to improve patient outcomes and satisfaction.
• Suppliers: The company's increasing production volumes provide opportunities for suppliers to grow their business.
• Creditors: The company's strong financial position reduces the risk of default on its debt obligations.

Next Steps

• Continue to grow the install base of robotic systems by driving adoption of Aquablation therapy among urologists.
• Increase system utilization by establishing Aquablation therapy as the surgical treatment of choice for BPH.
• Continue to broaden private payor coverage.
• Build upon the strong base of clinical evidence.
• Invest in high quality clinical research to support the use of Aquablation therapy for prostate cancer.
• Invest in research and development to drive continuous improvements and innovation.
• Drive increased awareness of Aquablation therapy beyond the urology community.
• Further penetrate and expand into existing and new international markets.

Key Dates